

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Austar Lifesciences Limited

奥星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6118)

VOLUNTARY ANNOUNCEMENT IN RELATION TO ACQUISITION OF TECHNOLOGY AND ANCILLARY BUSINESS

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest information in relation to the business development of the Company.

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company is pleased to announce that the Group, through an indirect wholly-owned subsidiary of the Company, has completed the acquisition (“**Acquisition**”) of the technology and ancillary business of 南京博健科技有限公司 (Nanjing Bojian Technology Co., Ltd.*) (“**Transferor**”).

The Transferor is a company established in the People’s Republic of China with limited liability in which the Group held 0.09% equity interest and is principally engaged in the equipment design and manufacture of liquid filling line and powder filling line for vials. Under the Acquisition, the Group has acquired from the Transferor (i) the Transferor’s technology of the products such as washing machine, sterilizing tunnel, filling line and cap machine; (ii) related intangible assets such as software copyright, trademark, domain name and other commercial symbols; and (iii) the personnel to carry out the target business including research and development, manufacturing, sales and after-sales service.

The integration of the filling line system and freeze-dryer system is an inevitable trend taking place in the pharmaceutical industry market. Through the Acquisition, it is expected that the Group will be able to better implement the strategic planning of freeze-drying and filling comprehensive solutions to be an integrated solutions provider of sterile injection production equipment by integrating the filling line product machine and the freeze-dryer system. Together with the Group’s strategic cooperation with ROTA (an associate of the Group), the Group will enhance the technology to offer clients customised sterile filling solutions for liquid and powder.

At the same time, by integrating with the Group's freeze-dryer and automatic loading and unloading device, the Group can provide clients with highly integrated sterile packaging system for lyophilized powder.

The Acquisition does not constitute a notifiable transaction or a connected transaction of the Company under Chapter 14 or Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited respectively.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 1 March 2022

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.

** For identification purpose only*